CY1120064T1 - Ινδολοκαρβονιτριλια ως επιλεκτικοι ρυθμιστες του υποδοχεα ανδρογονων - Google Patents

Ινδολοκαρβονιτριλια ως επιλεκτικοι ρυθμιστες του υποδοχεα ανδρογονων

Info

Publication number
CY1120064T1
CY1120064T1 CY20181100173T CY181100173T CY1120064T1 CY 1120064 T1 CY1120064 T1 CY 1120064T1 CY 20181100173 T CY20181100173 T CY 20181100173T CY 181100173 T CY181100173 T CY 181100173T CY 1120064 T1 CY1120064 T1 CY 1120064T1
Authority
CY
Cyprus
Prior art keywords
androgen receptor
indolocarvonitrilia
regulators
optional
optional regulators
Prior art date
Application number
CY20181100173T
Other languages
Greek (el)
English (en)
Inventor
Philip Stewart Turnbull
Rodolfo Cadilla
Original Assignee
Glaxosmithkline Intellectual Property (No. 2) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120064(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Intellectual Property (No. 2) Limited filed Critical Glaxosmithkline Intellectual Property (No. 2) Limited
Publication of CY1120064T1 publication Critical patent/CY1120064T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
CY20181100173T 2012-07-17 2018-02-13 Ινδολοκαρβονιτριλια ως επιλεκτικοι ρυθμιστες του υποδοχεα ανδρογονων CY1120064T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261672455P 2012-07-17 2012-07-17
US201361748874P 2013-01-04 2013-01-04
PCT/IB2013/001530 WO2014013309A1 (en) 2012-07-17 2013-07-15 Indolecarbonitriles as selective androgen receptor modulators

Publications (1)

Publication Number Publication Date
CY1120064T1 true CY1120064T1 (el) 2018-12-12

Family

ID=49117887

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100173T CY1120064T1 (el) 2012-07-17 2018-02-13 Ινδολοκαρβονιτριλια ως επιλεκτικοι ρυθμιστες του υποδοχεα ανδρογονων

Country Status (39)

Country Link
US (5) US8957104B2 (OSRAM)
EP (1) EP2875013B1 (OSRAM)
JP (1) JP6106746B2 (OSRAM)
KR (1) KR102127939B1 (OSRAM)
CN (1) CN104619693B (OSRAM)
AR (1) AR091770A1 (OSRAM)
AU (1) AU2013291721B2 (OSRAM)
BR (1) BR112015000940B1 (OSRAM)
CA (1) CA2879104C (OSRAM)
CL (1) CL2015000119A1 (OSRAM)
CO (1) CO7240378A2 (OSRAM)
CR (1) CR20150008A (OSRAM)
CY (1) CY1120064T1 (OSRAM)
DK (1) DK2875013T3 (OSRAM)
DO (1) DOP2015000004A (OSRAM)
EA (1) EA026371B8 (OSRAM)
ES (1) ES2657912T3 (OSRAM)
HR (1) HRP20180061T1 (OSRAM)
HU (1) HUE036238T2 (OSRAM)
IL (1) IL236448A (OSRAM)
IN (1) IN2014KN02993A (OSRAM)
JO (1) JO3384B1 (OSRAM)
LT (1) LT2875013T (OSRAM)
ME (1) ME02996B (OSRAM)
MX (1) MX349943B (OSRAM)
MY (2) MY173845A (OSRAM)
NZ (1) NZ703129A (OSRAM)
PE (1) PE20150371A1 (OSRAM)
PH (1) PH12015500104B1 (OSRAM)
PL (1) PL2875013T3 (OSRAM)
PT (1) PT2875013T (OSRAM)
RS (1) RS56810B1 (OSRAM)
SG (1) SG11201408493WA (OSRAM)
SI (1) SI2875013T1 (OSRAM)
SM (1) SMT201800115T1 (OSRAM)
TW (1) TWI574946B (OSRAM)
UY (1) UY34911A (OSRAM)
WO (1) WO2014013309A1 (OSRAM)
ZA (1) ZA201500096B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
RS56810B1 (sr) 2012-07-17 2018-04-30 Glaxosmithkline Ip No 2 Ltd Indolkarbonitrili kao selektivni modulatori androgen receptora
JP6556738B2 (ja) * 2014-01-21 2019-08-07 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited (r)−1−(1−(メチルスルホニル)プロパン−2−イル)−4−(トリフルオロメチル)インドリン−5−カルボニトリルの結晶形
MX2017004819A (es) * 2014-10-16 2018-06-12 Gtx Inc Metodos de tratamiento de transtornos urológicos usando sarm.
CN105130872B (zh) * 2015-08-25 2018-01-30 江西师范大学 一种3位三氟甲基取代吲哚的制备方法
CN110437125B (zh) * 2019-09-06 2021-03-12 苏州旺山旺水生物医药有限公司 一种Tezacaftor中间体II的制备方法
US20220306609A1 (en) * 2021-03-23 2022-09-29 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
CN115010574B (zh) * 2022-06-06 2024-01-05 爱斯特(成都)生物制药股份有限公司 1-溴-2-氯-4-氟-2碘苯的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL137718A0 (en) 1998-02-25 2001-10-31 Genetics Inst Inhibitors of phospholipase enzymes
RS50087B (sr) * 1998-06-19 2009-01-22 Pfizer Products Inc., Pirolo (2,3-d) pirimidin jedinjenja
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
JP4522851B2 (ja) 2002-05-24 2010-08-11 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト チオアルキルアミン誘導体の調製方法
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
CN1960973A (zh) * 2004-03-30 2007-05-09 惠氏公司 作为去甲肾上腺素(ne)与血清素(5-h t)活性和单胺重摄取的调控剂以治疗血管舒缩症状(vms)的1-(1h-吲哚-1-基)-3-(4-甲基哌嗪-1-基)-1-苯基丙烷-2-醇衍生物和相关化合物
WO2005110985A2 (en) 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Indole, benzofuran and benzothiophene derivatives as selective androgen receptor modulators (sarms)
WO2005111028A1 (en) 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
AU2005243238B2 (en) 2004-05-03 2011-11-10 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (SARMS)
WO2005118539A1 (en) * 2004-06-01 2005-12-15 F.Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor
MX2008001334A (es) * 2005-07-29 2008-03-24 Pfizer Prod Inc Derivados de pirrolo [2,3-d]pirimidina, sus intermedios y sintesis.
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
MX2008011791A (es) * 2006-03-15 2008-09-25 Wyeth Corp Azaciclilaminas-n-sustituidas como antagonistas de histamina-3.
CN101426778A (zh) * 2006-03-15 2009-05-06 惠氏公司 作为组胺-3拮抗剂的n-经取代-氮杂环基胺
JP5275236B2 (ja) 2006-09-29 2013-08-28 スミスクライン ビーチャム コーポレーション 置換されたインドール化合物
PT2384326E (pt) * 2008-08-20 2014-06-09 Zoetis Llc Compostos de pirrolo[2,3-d]pirimidina
WO2010118287A1 (en) 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
EP2488524B1 (en) * 2009-10-15 2013-07-03 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
JP5739446B2 (ja) * 2009-12-18 2015-06-24 ファイザー・インク ピロロ[2,3−d]ピリミジン化合物
CN103415289B (zh) 2010-07-07 2017-04-12 得克萨斯州大学系统董事会 前神经原性化合物
MX351305B (es) * 2011-01-20 2017-10-09 Merck Sharp & Dohme Antagonistas del receptor de mineralocorticoides.
SMT201800497T1 (it) * 2011-12-21 2018-11-09 Shanghai hengrui pharmaceutical co ltd Derivato di pirrolo ad anello eteroarilico a sei elementi, relativo metodo di preparazione, e relativi usi medicinali
RS56810B1 (sr) * 2012-07-17 2018-04-30 Glaxosmithkline Ip No 2 Ltd Indolkarbonitrili kao selektivni modulatori androgen receptora
JP6556738B2 (ja) * 2014-01-21 2019-08-07 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited (r)−1−(1−(メチルスルホニル)プロパン−2−イル)−4−(トリフルオロメチル)インドリン−5−カルボニトリルの結晶形

Also Published As

Publication number Publication date
KR102127939B1 (ko) 2020-06-29
SG11201408493WA (en) 2015-02-27
WO2014013309A1 (en) 2014-01-23
RS56810B1 (sr) 2018-04-30
MX349943B (es) 2017-08-21
IL236448A0 (en) 2015-02-26
PH12015500104A1 (en) 2015-03-02
US10710963B2 (en) 2020-07-14
UY34911A (es) 2014-02-28
SMT201800115T1 (it) 2018-03-08
MX2015000825A (es) 2015-07-17
SI2875013T1 (en) 2018-03-30
CN104619693B (zh) 2019-08-13
US10196353B2 (en) 2019-02-05
BR112015000940A2 (pt) 2017-06-27
AU2013291721B2 (en) 2016-02-25
US20170073309A1 (en) 2017-03-16
EA201492237A1 (ru) 2015-06-30
ME02996B (me) 2018-10-20
CA2879104A1 (en) 2014-01-23
CN104619693A (zh) 2015-05-13
BR112015000940B1 (pt) 2022-05-17
KR20150032333A (ko) 2015-03-25
IN2014KN02993A (OSRAM) 2015-05-08
HK1208867A1 (en) 2016-03-18
TWI574946B (zh) 2017-03-21
EA026371B1 (ru) 2017-03-31
EP2875013A1 (en) 2015-05-27
JP6106746B2 (ja) 2017-04-05
LT2875013T (lt) 2018-02-26
US20200270210A1 (en) 2020-08-27
JO3384B1 (ar) 2019-03-13
ES2657912T3 (es) 2018-03-07
US8957104B2 (en) 2015-02-17
US20150080449A1 (en) 2015-03-19
AU2013291721A1 (en) 2015-02-26
CL2015000119A1 (es) 2015-04-24
HRP20180061T1 (hr) 2018-02-23
PH12015500104B1 (en) 2015-03-02
EP2875013B1 (en) 2017-11-29
CA2879104C (en) 2020-08-25
US11299457B2 (en) 2022-04-12
DOP2015000004A (es) 2015-03-15
IL236448A (en) 2016-10-31
CR20150008A (es) 2015-03-09
PL2875013T3 (pl) 2018-06-29
PT2875013T (pt) 2018-02-28
MY198512A (en) 2023-09-01
ZA201500096B (en) 2017-07-26
HUE036238T2 (hu) 2018-06-28
PE20150371A1 (es) 2015-03-27
MY173845A (en) 2020-02-24
CO7240378A2 (es) 2015-04-17
US20140024694A1 (en) 2014-01-23
DK2875013T3 (en) 2018-01-22
EA026371B8 (ru) 2017-06-30
US20190127326A1 (en) 2019-05-02
NZ703129A (en) 2017-06-30
TW201416349A (zh) 2014-05-01
JP2015522603A (ja) 2015-08-06
AR091770A1 (es) 2015-02-25
US9533948B2 (en) 2017-01-03

Similar Documents

Publication Publication Date Title
CY1120064T1 (el) Ινδολοκαρβονιτριλια ως επιλεκτικοι ρυθμιστες του υποδοχεα ανδρογονων
CY1119590T1 (el) Ρυθμιστες dll3 και μεθοδοι χρησης
CY1122227T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
CY1122308T1 (el) St2l ανταγωνιστες και μεθοδοι χρησης
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
CY1119531T1 (el) Ενωσεις και συνθεσεις για την ρυθμιση της δραστηριοτητας toy egfr
IL265014B (en) Retroviral transduction using poloxamers
CO7151485A2 (es) Anticuerpos anti-sez6 y métodos de empleo
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
UA109931C2 (xx) Піримідинциклогексильні модулятори глюкокортикоїдних рецепторів
CY1118860T1 (el) Νεα διαζασπειροκυκλοαλκανια και αζασπειροκυκλοαλκανια
CR20150048A (es) Anticuerpos e inmunoconjugados anti-cd22
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
CR20150120A (es) Nuevos derivados bicíclicos
EP2873157A4 (en) MULTIMODAL TRANSMITTERS FOR HIGH-POWER SPECTRUM EFFICIENT COMMUNICATIONS
LT3377483T (lt) N-pakeistieji indolo dariniai kaip pge2 receptoriaus moduliatoriai
BR112015012907A2 (pt) composição de cuidado pessoal
SI3160948T1 (sl) Amidi benzoksazinona, kot modulatorji receptorja mineralokortikoida
DK2825558T3 (da) Kombinationsterapi til behandling af ovariecancer
HUE049492T2 (hu) Magéleterõ modulálása